Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 20, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $251.68 to $253,000,000.00.

Highlighted Stocks Traded by Insiders:

UDR (UDR) - FREE Research Report

OShields William T III who is Vice President - Treasurer at UDR sold 4,800 shares at $25.47 on March 20, 2014. Following this transaction, the Vice President - Treasurer owned 5,590 shares meaning that the stake was reduced by 46.2% with the 4,800-share transaction.

The shares most recently traded at $25.53, up $0.06, or 0.24% since the insider transaction. Historical insider transactions for UDR go as follows:

  • 4-Week # shares sold: 12,000
  • 12-Week # shares sold: 12,000
  • 24-Week # shares sold: 29,000

The average volume for UDR has been 1.7 million shares per day over the past 30 days. UDR has a market cap of $6.3 billion and is part of the financial sector and real estate industry. Shares are up 7.79% year-to-date as of the close of trading on Thursday.

UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities. The stock currently has a dividend yield of 3.64%. Currently there are 3 analysts that rate UDR a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UDR - FREE

TheStreet Quant Ratings rates UDR as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, revenue growth and growth in earnings per share. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full UDR Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 15,000 shares at $9.73 on March 20, 2014. Following this transaction, the CEO & Chairman owned 139.6 million shares meaning that the stake was reduced by 0.01% with the 15,000-share transaction.

The shares most recently traded at $9.36, down $0.37, or 3.99% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.1 million shares per day over the past 30 days. Opko Health has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 14.46% year-to-date as of the close of trading on Thursday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

La-Z-Boy (LZB) - FREE Research Report

Mueller Margaret L who is Chief Accounting Officer at La-Z-Boy sold 3,750 shares at $27.88 on March 20, 2014. Following this transaction, the Chief Accounting Officer owned 11,130 shares meaning that the stake was reduced by 25.2% with the 3,750-share transaction.

The shares most recently traded at $28.30, up $0.42, or 1.48% since the insider transaction. Historical insider transactions for La-Z-Boy go as follows:

  • 4-Week # shares bought: 350
  • 4-Week # shares sold: 1,460
  • 12-Week # shares bought: 350
  • 12-Week # shares sold: 1,460
  • 24-Week # shares bought: 350
  • 24-Week # shares sold: 1,460

The average volume for La-Z-Boy has been 472,000 shares per day over the past 30 days. La-Z-Boy has a market cap of $1.4 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 10.81% year-to-date as of the close of trading on Thursday.

La-Z-Boy Incorporated manufactures, markets, imports, distributes, and retails upholstery products, accessories, and casegoods furniture products in the United States and Canada. The company also produces reclining chairs and manufactures/distributes residential furniture in the United States. The stock currently has a dividend yield of 0.86%. The company has a P/E ratio of 24.4. Currently there are 3 analysts that rate La-Z-Boy a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LZB - FREE

TheStreet Quant Ratings rates La-Z-Boy as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full La-Z-Boy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null